CHEK2 and cancer: Most CHEK2-deficient cancers presented with the clock-like mutational signatures SBS1 (5/16 cancers; 31%) and/or SBS5 (14/16 cancers; 88%; Figure 1, D, Supplementary Table 1, available online).